Last Updated: June 28, 2026 | Version 1.2
The landscape of metabolic health coverage is shifting. For millions of Medicare beneficiaries, the historical exclusion of weight loss medications from Part D has been a significant barrier to accessing life-changing treatments like semaglutide and tirzepatide. However, as of July 1, 2026, a new pathway has opened: the Medicare GLP-1 Bridge.
This article provides a comprehensive data report on the Bridge demonstration, its eligibility tiers, drug inclusions, and the specific mechanics that distinguish it from standard Part D coverage.
Key Findings: The 2026 Medicare GLP-1 Bridge at a Glance
- Fixed Cost: Participants pay a flat $50 monthly copay regardless of their current Part D benefit phase.
- Demonstration Period: The program is authorized to run from July 1, 2026, through December 31, 2027.
- Targeted Access: Only three specific branded medications (Foundayo, Wegovy, and Zepbound KwikPen) are eligible; Ozempic and Mounjaro remain excluded from this specific program.
- Eligibility Tiers: Access is determined by BMI and specific comorbidities, ranging from a BMI of 27 to 35+.
- External Logic: The Bridge operates outside the standard Part D financial risk model, utilizing a centralized processor to bypass traditional plan hurdles.
- No Compounding: Compounded GLP-1 medications are strictly excluded from the Bridge coverage.
Headline Statistic: The $50 Access Point
"Under the Medicare GLP-1 Bridge, the patient's out-of-pocket cost is capped at $50 per month: a reduction of over 90% compared to the standard retail cash price of branded weight loss medications." : Source: CMS.gov Section 402(a)(1)(A) Demonstration Data, 2026
Methodology: How This Report Was Compiled
This report is based on Tier 1 primary sources, including the Centers for Medicare & Medicaid Services (CMS) demonstration fact sheets and FAQs, Social Security Act legislative text, FDA drug labels, fiscal analysis from KFF (Kaiser Family Foundation), and pharmacy-facing coverage details published by NCPA. Our research team analyzed the official program parameters released in the Q2 2026 CMS technical guidance to provide beneficiaries with an accurate, non-promotional breakdown of the Bridge's operations.[1][2][3][4]
1. The Bridge is a Short-Term CMS Demonstration You Should Know About
The Medicare GLP-1 Bridge is not a permanent change to federal law. Instead, it is a time-limited demonstration project authorized under Section 402(a)(1)(A) of the Social Security Amendments of 1967. This specific legislative authority allows CMS to test new payment and service delivery models that have the potential to reduce program expenditures while maintaining or improving the quality of care.
The Bridge is scheduled to run from July 1, 2026, through December 31, 2027.[2] Its primary purpose is to gather real-world data on the clinical outcomes and fiscal impact of providing GLP-1 coverage for weight management before Congress considers a permanent repeal of the 2003 Medicare Modernization Act’s exclusion of weight loss drugs. For patients, this means the "Bridge" is exactly what the name implies: a temporary span intended to support beneficiaries until more permanent policy solutions: or the delayed BALANCE Model: can be implemented.
2. Coverage Exists Outside the Standard Part D Benefit
One of the most confusing aspects of the Bridge is that it does not function like your typical prescription drug coverage. Usually, when you fill a prescription, your Part D plan (like a SilverScript or UnitedHealthcare plan) decides the formulary, handles the prior authorization, and bears the financial risk.
Under the Bridge, Part D sponsors do not bear financial risk and do not need to "opt in" to the program. The coverage is provided "outside" the standard Part D benefit flow. This means:
- The Part D deductible does not apply to these drugs.
- No portion of the $50 copay or the drug cost counts toward your True Out-of-Pocket (TrOOP) costs.
- The $50 copay applies regardless of which Part D benefit phase you are in.[1][2]
This "carve-out" approach was designed to allow CMS to bypass the complex negotiations and mid-year formulary restrictions that usually prevent new drug coverage from being added quickly to Medicare.[1][2]
3. Which Specific Drugs You Should Know are Covered
The Bridge is highly selective regarding which medications are included. It does not cover every GLP-1 on the market. Only drugs specifically FDA-approved for chronic weight management (and their manufacturers who agreed to the Bridge's pricing terms) are eligible.
Eligible Medications:
- Foundayo: All formulations and dose strengths.
- Wegovy (semaglutide): All formulations, including both the traditional subcutaneous injections and the newer tablet versions.
- Zepbound (tirzepatide): KwikPen formulation only. It is critical to note that the single-dose vial and the standard single-dose pen versions of Zepbound are currently not included in the Bridge coverage.
Excluded Medications:
- Ozempic and Mounjaro: Because these are FDA-approved specifically for Type 2 Diabetes, they are already coverable under standard Part D (if the patient has diabetes). They are not part of the Weight Loss Bridge.
- Rybelsus and Saxenda: These do not currently meet the pricing or demonstration criteria for the 2026-2027 Bridge.
- Compounded GLP-1s: There is no coverage for compounded versions of semaglutide or tirzepatide. For a deeper look at why these are excluded, see our FDA compounding crackdown analysis.
The covered-drug list above reflects CMS program materials and pharmacy-facing implementation guidance published by NCPA.[2][4]
4. Costs You Should Know: The $50 Fixed Copay
For the duration of the Bridge (July 2026 – December 2027), the cost-sharing for eligible beneficiaries is simplified to a $50 monthly copay. This is a flat rate.[1][2]
Unlike standard Part D drugs, where you might pay 25% coinsurance or hit a high deductible in January, the Bridge price remains $50 in every phase of the benefit. It is also important to note that the Low-Income Subsidy (LIS), often referred to as "Extra Help," does not apply to the Bridge. Even if you normally have $0 or $11 copays for other drugs through LIS, the Bridge medications will still require the $50 flat fee.[1]
While $50 may be higher than some Tier 1 generic copays, it represents a massive saving compared to the out-of-pocket costs most seniors face. According to our GLP-1 cost guide, cash-pay prices for these same medications can exceed $1,000 per month without insurance.
5. The $245 Manufacturer Net Price Explained
You might wonder how a $1,000 drug becomes $50 for a senior. The "Bridge" is built on a specific financial agreement between CMS and the drug manufacturers (Eli Lilly, Novo Nordisk, and the makers of Foundayo).[1][2]
The manufacturers have agreed to a net price of $245 per monthly supply for drugs dispensed through the Bridge. But that does not mean the pharmacy is paid only $245, and it does not mean CMS simply pays a flat $195 subsidy.
The actual flow works like this:
- The Patient pays a $50 copay at the pharmacy.[1]
- The Pharmacy is reimbursed by the CMS central processor at no lower than the drug's wholesale acquisition cost (WAC), minus the $50 beneficiary copay, plus a dispensing fee (and applicable taxes, where relevant).[1][2]
- The Manufacturer then owes money back to CMS for the difference between the drug's WAC and the negotiated $245 net price.[3]
In other words, the $245 figure is a manufacturer net price benchmark, not the same thing as the pharmacy reimbursement amount. CMS uses the central processor to make the pharmacy whole based on WAC-based reimbursement, then reconciles the manufacturer payment separately. That structure is a major reason the Bridge can operate outside the normal Part D benefit flow.[1][2][3]
This negotiated rate is significant because it is far lower than the "list price" seen in the commercial market. By separating pharmacy reimbursement from the manufacturer's final net price, CMS is testing whether broader access to obesity treatment can be delivered in a controlled way before any permanent Medicare policy change.[1][3]
6. How the Central Processor Works
Because the Bridge operates outside of your private Part D plan, a different system handles the paperwork. CMS utilizes a single central processor to manage the program.[1][2]
CMS publicly describes this as a centralized CMS claims processing system that handles the operational flow for the Bridge. By using this central processor, the Bridge can:
- Instantly Adjudicate Claims: The pharmacy sends the claim to the central processor instead of your Part D provider.
- Verify Eligibility: The processor checks the prior authorization (PA) on file.
- Pay the Pharmacy: The pharmacy collects your $50 and receives the rest of the reimbursement through the central processor.[1][2]
This means you don't have to wait for your specific insurance company to "update their formulary." If you are eligible, the Bridge is available at any participating Medicare pharmacy starting July 1, 2026.[1][2]
7. Eligibility Tiers and Clinical Requirements You Should Know
You cannot simply ask for these drugs because you want to lose 10 pounds. The Bridge is strictly regulated by clinical eligibility tiers based on Body Mass Index (BMI) and "comorbidities" (other health conditions).
The Three Tiers of Eligibility:
- Tier 1 (High BMI): Beneficiaries with a BMI ≥ 35. At this level, no additional health conditions are required for coverage.
- Tier 2 (Moderate BMI + Major Condition): Beneficiaries with a BMI ≥ 30 AND at least one of the following:
- Heart failure with preserved ejection fraction (HFpEF).
- Uncontrolled hypertension (high blood pressure).
- Chronic Kidney Disease (CKD) Stage 3a or higher.
- Tier 3 (Overweight + Specific Risk): Beneficiaries with a BMI ≥ 27 AND at least one of the following:
- Prediabetes.
- History of myocardial infarction (heart attack).
- History of stroke.
- Symptomatic peripheral artery disease (PAD).
Prior authorization from a healthcare provider is non-negotiable. Your doctor must submit documentation of your BMI and the qualifying condition to the central processor before the $50 copay will be authorized at the pharmacy.
8. Critical Exclusions You Should Know
The Bridge is designed specifically for those who currently have no other way to get GLP-1s covered. This leads to some strict exclusions that may surprise beneficiaries.
You are NOT eligible for the Bridge if:
- You already have Part D coverage for the drug: If you are taking Ozempic or Wegovy for Type 2 Diabetes or to reduce the risk of major cardiovascular events (under the 2024 expanded Wegovy label), you must stay within your standard Part D benefit. You cannot "switch" to the Bridge just to get the $50 price.
- You have a "Coverable" Condition: If you have been diagnosed with Type 2 Diabetes, moderate-to-severe Obstructive Sleep Apnea (OSA), or noncirrhotic MASH with moderate-advanced fibrosis, you are excluded from the Bridge. This is because CMS expects these conditions to be covered by the standard Part D plans under existing medical necessity rules.
This creates a "catch-22" for some: the Bridge is only for those whose primary medical need for the drug is weight management and the prevention of the conditions listed in the eligibility tiers. For a broader look at how these rules interact, consult our broader Medicare GLP-1 coverage guide.
9. Why the BALANCE Model Delay Matters
To understand why the Bridge exists, we have to look at the BALANCE Model. This was a more permanent, systemic change proposed for Medicare Part D that would have integrated weight loss drug coverage into the standard insurance risk pool.
However, on April 21, 2026: the day after the Part D application deadline: CMS announced that the BALANCE Model would be indefinitely delayed.[3] The central issue was insufficient participation from major Part D plan sponsors. Under the original design, CMS needed the 80% participation threshold among Part D plans to move forward, and that threshold was not met.[3]
The Bridge was extended through late 2027 specifically to fill the gap left by this delay. KFF's analysis of the CMS action points to the same core problem: major Part D sponsors were reluctant or unwilling to participate in BALANCE as originally structured, so CMS kept the Bridge in place while it gathers more utilization data and weighs future redesign options.[3] If the Bridge is successful, it provides the data needed to eventually launch the BALANCE Model or a similar permanent program.
10. This is Not Permanent Part D Coverage
The most important thing to remember is the "sunset" date: December 31, 2027.
Unless Congress acts to change the law or CMS issues a new demonstration extension, the Bridge coverage: and the $50 copay: will disappear on January 1, 2028. This creates a potential "coverage cliff" for seniors who may be on these medications for 18 months only to face full retail prices again at the end of the program.
Patients and caregivers should use the Bridge period to work closely with their doctors on long-term metabolic health strategies. Furthermore, as the "shortage era" of these drugs comes to an end, it is vital to stay informed on the legitimacy of your sources. Avoid unauthorized telehealth shortcuts; instead, review our guide on FDA warning letters for telehealth patients to ensure you are receiving authentic, Bridge-eligible medication.
Comparison: Standard Part D vs. The Medicare GLP-1 Bridge (2026)
| Feature | Standard Part D (Weight Loss) | Medicare GLP-1 Bridge |
|---|---|---|
| Coverage Status | Statutorily Excluded | Covered via Demonstration |
| Monthly Copay | N/A (Full Cash Price) | $50 Flat Fee |
| Deductible | Applies to most plans | Does Not Apply |
| Eligible Drugs | None (for weight loss) | Foundayo, Wegovy, Zepbound (KwikPen) |
| Net Drug Price | ~$900 – $1,100 | $245 (Negotiated) |
| Duration | Permanent Exclusion | July 2026 – Dec 2027 |
| Processor | Individual Part D Plan | Central Processor |
What it Means for Patients: Navigating the Bridge
If you believe you meet the BMI and comorbidity criteria, your next steps are critical. Because this program uses a central processor, your local pharmacist might be your best ally.
- Verify Your BMI: Schedule a "Wellness Visit" with your primary care provider to get an official weight and height measurement recorded in your Medicare file.
- Confirm Comorbidities: Ensure your doctor has coded your hypertension, prediabetes, or heart failure correctly. The Bridge processor relies on "ICD-10" codes to trigger the $50 copay.
- Request the Correct Drug/Device: Remember that for Zepbound, only the KwikPen is covered. If your doctor writes a script for the "Single-Dose Vial," the claim will be rejected by the Bridge processor.
- Check Your Pharmacy: Most major retail pharmacies and Medicare-contracted independent pharmacies are equipped to handle Bridge claims through the central processor, but call ahead to ensure they are familiar with the "2026 GLP-1 Bridge Processing Manual."
For those who do not qualify for the Bridge or find the $50 copay still out of reach, comparing branded vs. compounded pricing comparison remains a necessary step, though you must weigh the safety and legal warnings associated with non-Bridge medications.
What it Means for the Market: The "Manufacturer's Bet"
Eli Lilly and Novo Nordisk are participating in the Bridge at a significantly reduced "net price" of $245. This is a strategic move. By proving that 1.5 million seniors can successfully use these drugs at a $50 price point with manageable side effects and high adherence, the manufacturers are building the political case for permanent Medicare coverage.
For the healthcare industry, the Bridge is the ultimate stress test for the GLP-1 supply chain. If pharmacies can't keep Wegovy or Zepbound KwikPens in stock during the Bridge, it will be much harder to convince Congress to make the coverage permanent in 2028.
FAQ: Common Questions About the Medicare GLP-1 Bridge
Can I use a manufacturer coupon with the $50 Bridge copay?
No. Federal anti-kickback statutes generally prohibit the use of manufacturer "co-pay cards" or coupons for any medication covered by a federal healthcare program like Medicare, including the Bridge demonstration. The $50 copay is already the subsidized "final price."
What happens if I move from Tier 3 to Tier 1?
If your health status changes (e.g., your BMI increases or you develop a new qualifying condition like CKD), your doctor simply needs to submit an updated prior authorization. The $50 copay remains the same regardless of which tier you fall into.
Is there a limit on how many months I can be on the Bridge?
The only limit is the program's end date: December 31, 2027. There is no specific "cap" on the number of fills an individual can receive, provided they maintain clinical eligibility and a valid prescription for weight reduction or maintenance.
Does the Bridge cover the "starter doses" or only maintenance?
The Bridge covers the full titration schedule (starter doses) and the maintenance doses for all eligible drugs. The clinical criteria specifically mention "maintenance of weight reduction," acknowledging that these are often long-term or lifelong medications.
Why is the Zepbound Single-Dose Vial excluded?
According to CMS technical guidance, the Bridge's pricing agreement was tied to specific "National Drug Codes" (NDCs). At the time of the program's launch, the manufacturer agreement for the $245 net price only extended to the KwikPen delivery system for Zepbound.
Conclusion: A Temporary Opportunity
The 2026 Medicare GLP-1 Bridge represents a historic: though temporary: shift in how the federal government views obesity treatment for seniors. For the first time, the "weight loss exclusion" has a functional workaround for those with the highest clinical need.
As we move through 2026 and into 2027, the data generated by this "Bridge" will likely dictate the future of metabolic health in America for the next decade. If you are a beneficiary, stay in close contact with your medical team, monitor the published review methodology of your telehealth or clinical providers, and ensure you are taking full advantage of this window of access while it remains open.
References
[1] CMS. Medicare GLP-1 Bridge Expectations and FAQs (PDF), retrieved June 28, 2026.
[2] CMS. Medicare GLP-1 Bridge webpage, retrieved June 28, 2026.
[3] KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge, retrieved June 28, 2026.
[4] NCPA. CMS updates website on Medicare GLP-1 Bridge, retrieved June 28, 2026.
Corrected 9 October 2026. We removed 4 generated images from this article. Generated images on this site no longer show certifications, organisations, products, prices or figures unless the specific claim has been checked.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication. Eligibility for the Medicare GLP-1 Bridge is determined by CMS and clinical criteria; individual results and coverage may vary.
Keep exploring our GLP-1 resources:
